Edwards Lifesciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Edwards Lifesciences wird ein jährliches Gewinn- und Umsatzwachstum von 9.7% bzw. 8.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.6% betragen.

Wichtige Informationen

7.5%

Wachstumsrate der Gewinne

5.3%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.4%
Wachstumsrate der Einnahmen	8.4%
Zukünftige Eigenkapitalrendite	23.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	16 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Feb 08

Recent updates

Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut

Jul 26

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Jul 26

Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Jul 12

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Jun 24

Edwards Lifesciences Corp Looks Bullish (Technical Analysis)

Jun 22

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

May 13

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)

Feb 14

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Feb 08

Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

Jan 28

The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Jan 14

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Jan 09

Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Dec 31

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Dec 17

Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets

Oct 26

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Oct 23

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Oct 09

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Sep 26

A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Sep 11

Edwards Lifesciences: Rising Dominance In Structural Heart Disease

Aug 21

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Jul 16

Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?

Jun 30

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Jun 15

Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed

Jun 12

Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?

May 31

Gewinn- und Umsatzwachstumsprognosen

NYSE:EW - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	7,702	1,956	1,685	2,020	15
12/31/2025	7,043	1,787	1,598	1,835	16
12/31/2024	6,481	1,530	1,376	1,713	18
6/30/2024	6,204	1,540	552	866	N/A
3/31/2024	6,114	1,428	251	528	N/A
12/31/2023	6,005	1,402	630	896	N/A
9/30/2023	5,362	1,341	775	1,042	N/A
6/30/2023	5,201	1,300	669	940	N/A
3/31/2023	5,279	1,451	972	1,239	N/A
12/31/2022	5,382	1,522	953	1,218	N/A
9/30/2022	5,364	1,459	1,040	1,309	N/A
6/30/2022	5,355	1,455	1,261	1,531	N/A
3/31/2022	5,357	1,539	1,428	1,725	N/A
12/31/2021	5,233	1,503	1,402	1,732	N/A
9/30/2021	5,095	1,477	1,409	1,758	N/A
6/30/2021	4,925	1,462	1,050	1,443	N/A
3/31/2021	4,474	851	717	1,148	N/A
12/31/2020	4,386	823	647	1,054	N/A
9/30/2020	4,369	794	692	1,057	N/A
6/30/2020	4,322	744	941	1,279	N/A
3/31/2020	4,484	1,108	1,087	1,389	N/A
12/31/2019	4,348	1,047	905	1,183	N/A
9/30/2019	4,152	774	809	1,073	N/A
6/30/2019	3,964	725	705	978	N/A
3/31/2019	3,821	765	523	777	N/A
12/31/2018	3,723	722	685	927	N/A
9/30/2018	3,634	712	754	998	N/A
6/30/2018	3,549	657	772	966	N/A
3/31/2018	3,447	560	N/A	1,024	N/A
12/31/2017	3,435	584	N/A	1,001	N/A
9/30/2017	3,315	745	N/A	838	N/A
6/30/2017	3,232	716	N/A	733	N/A
3/31/2017	3,150	657	N/A	726	N/A
12/31/2016	2,964	570	N/A	704	N/A
9/30/2016	2,867	552	N/A	607	N/A
6/30/2016	2,743	528	N/A	604	N/A
3/31/2016	2,601	515	N/A	584	N/A
12/31/2015	2,494	495	N/A	550	N/A
9/30/2015	2,441	463	N/A	539	N/A
6/30/2015	2,433	440	N/A	349	N/A
3/31/2015	2,391	874	N/A	957	N/A
12/31/2014	2,323	811	N/A	1,022	N/A
9/30/2014	2,241	777	N/A	1,040	N/A
6/30/2014	2,129	759	N/A	1,160	N/A
3/31/2014	2,071	306	N/A	511	N/A
12/31/2013	2,046	389	N/A	473	N/A
9/30/2013	2,020	405	N/A	476	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EWDas prognostizierte Gewinnwachstum (9.7% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: EWDie Erträge des Unternehmens (9.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: EWDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: EWDie Einnahmen des Unternehmens (6.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: EWDie Einnahmen des Unternehmens (8.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: EWDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.6%)

Edwards Lifesciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Recent updates

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 27%

Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024

Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million.

Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E

Now 15% overvalued

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Edwards Lifesciences Corp Looks Bullish (Technical Analysis)

Now 20% overvalued

Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Corporate VP & CFO notifies of intention to sell stock

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Insider notifies of intention to sell stock

Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)

Non-Executive Chairman of the Board exercised options and sold US$1.4m worth of stock

When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Announces the Release of Data from the Hudle Study

Now 22% overvalued after recent price rise

Corporate VP & CFO notifies of intention to sell stock

Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Non-Executive Chairman of the Board exercised options and sold US$1.5m worth of stock

Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Insider notifies of intention to sell stock

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Non-Executive Chairman of the Board exercised options and sold US$1.5m worth of stock

Investor sentiment improves as stock rises 18%

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024

Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Corporate VP & CFO notifies of intention to sell stock

Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Non-Executive Chairman of the Board exercised options and sold US$1.1m worth of stock

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Insider notifies of intention to sell stock

Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

Third quarter 2023 earnings: EPS exceeds analyst expectations

Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Insider exercised options and sold US$214k worth of stock

Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark

Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Insider notifies of intention to sell stock

A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Corporate VP & CFO notifies of intention to sell stock

Edwards Lifesciences: Rising Dominance In Structural Heart Disease

Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry

Non-Executive Chairman of the Board exercised options and sold US$1.3m worth of stock

Insufficient new directors